Nama Insights

Alvotech (ALVO)

Healthcare · Drug Manufacturers Specialty Generic · NASDAQ

Alvotech (ALVO) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $1.53B and a free-cash-flow yield of -12.1%. Over the most recent reported fiscal year, revenue grew 19.7%. Nama's AI scorecard rates it Sell, 2.8 out of 10. On 12-month momentum it ranks in the lagging band of its market.
AI scorecard
Sell · 2.8/10
Clearly negative, short of the bottom band. As of Nov 20, 2026.
Momentum
Lagging · +1.4% over 12 months ex. last
Second-worst fifth of its market on the past year's move.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-77.1%
How far the last close sits under the highest price of the past five years.
Market cap$1.53B
Trailing P/E—
Price / book—
Price / sales3.1
FCF yield-12.1%
Dividend yield—
Gross margin60.5%
Operating margin9.7%
Net margin-36.5%
Revenue growth (YoY)+19.7%
Revenue growth (3-yr annual)+91.8%
EPS growth (YoY)—
FCF/share growth (YoY)—
Beta0.2
ExchangeNASDAQ
SectorHealthcare
IndustryDrug Manufacturers Specialty Generic

ALVO earnings

Next report: Mar 10, 2027 (Q4 2026, EPS estimate -$0.05). Beat the EPS estimate in 2 of 4 recent quarters.

QuarterReportedEPSEstimateSurpriseRevenue
Q3 2026 Nov 10, 2026 -$0.03 -$0.05 +40.0% $111.40M
Q2 2026 Aug 19, 2026 -$0.11 -$0.08 -37.5% $105.77M
Q1 2026 May 5, 2026 -$0.09 -$0.07 -28.6% $105.86M
Q4 2025 Mar 17, 2026 $0.01 -$0.01 +200.0% $166.57M

ALVO analyst price target

Median target $8.00 from 6 analysts, ranging $4.00 – $9.00.

Drug Manufacturers Specialty Generic peers

TickerCompanyMarket capP/E
TAK Takeda Pharmaceutical $68.40B 43.7
TEVA Teva Pharmaceutical Industries $44.97B 16.3
HLN Haleon $39.67B 21.1
ZTS Zoetis $32.83B 12.2
UTHR United Therapeutics $23.81B 21.1
VTRS Viatris $22.79B 7.8
NBIX Neurocrine Biosciences $15.85B 15.7
ELAN Elanco Animal Health $13.14B 23.1
Explore live ALVO data on Nama Insights →

ALVO FAQ

Is ALVO a buy?
Nama's AI scorecard currently rates Alvotech Sell (2.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does ALVO report earnings?
Alvotech's next scheduled report is on Mar 10, 2027. Analysts expect EPS of -$0.05.
What is the ALVO price target?
The median analyst price target from 6 analysts is $8.00, with a range of $4.00 – $9.00.
Is ALVO Shariah compliant?
Nama's AAOIFI-style screen reads Alvotech as Not Shariah Compliant. At least one of the three ratios or the industry test failed.